A Case of Bilateral Breast Cancer in which Cancer Multi-gene Panel Testing Contributed to Treatment

DOI Web Site Web Site 8 References
  • KATO Kimika
    Department of Breast Surgical Oncology, Osaka Metropolitan University Graduate School of Medicine
  • MORISAKI Tamami
    Department of Breast Surgical Oncology, Osaka Metropolitan University Graduate School of Medicine
  • TAKADA Koji
    Department of Breast Surgical Oncology, Osaka Metropolitan University Graduate School of Medicine
  • GOTO Wataru
    Department of Breast Surgical Oncology, Osaka Metropolitan University Graduate School of Medicine
  • KASHIWAGI Shinichiro
    Department of Breast Surgical Oncology, Osaka Metropolitan University Graduate School of Medicine

Bibliographic Information

Other Title
  • がん遺伝子パネル検査が治療方針に寄与した両側乳癌の1例
  • ガン イデンシ パネル ケンサ ガ チリョウ ホウシン ニ キヨ シタ リョウガワ ニュウガン ノ 1レイ

Search this article

Abstract

<p>Here, we report a case in which cancer multi-gene panel testing contributed to treatment. The patient was a 59-year-old woman. She was referred to our hospital for suspected left breast cancer with skin invasion. The right breast presented with invasive ductal carcinoma cT1N1M0 stage IIA (Luminal HER) and the left one with invasive ductal carcinoma cT4N3M0 stage IIIC (Luminal). The patient was treated with combination chemotherapy (docetaxel+pertuzumab+trastuzumab), and surgery was performed after tumor shrinkage was observed. Postoperatively, the patient was administered with adjuvant chemotherapy and endocrine therapy according to the subtype. One year postoperatively, treatment was switched due to the recurrence of bone metastases in the cervical and thoracic spine, followed by liver metastasis after 6 months. Liver biopsy was performed to reconfirm the subtype, and treatment was switched again. The patient was treated successfully, although adverse events rendered the continuation of treatment difficult after approximately 6 months. Therefore, cancer multi-gene panel testing (FoundationOne®) was performed, and a germline mutation in the BRCA2 gene was confirmed. We strongly recommend the inclusion of multi-gene panel testing in cancer management, as it may offer new treatment opportunities.</p>

Journal

References(8)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top